Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value
Kelun-Biotech Biopharma
Innovative ADCs and Drug Conjugates for Patients Worldwide
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines
China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point. Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary…
Livzon/Kanova’s Lecankitug Gets China Approval After Beating Secukinumab in Phase 3 Psoriasis Trial
China’s National Medical Products Administration (NMPA) has approved lecankitug (LZM012/XKH004), an IL-17A/IL-17F-targeting monoclonal antibody jointly developed by Livzon Pharmaceutical Group and Beijing Kanova Biopharmaceutical, for the treatment of…
AusperBio Raises $120 Million Series C to Advance AHB-137 Toward Hepatitis B Functional Cure and Commercialization
AusperBio has raised $120 million in Series C financing to advance its lead chronic hepatitis B therapy AHB-137 through Phase III development and prepare for potential commercialization, while expanding a next-generation pipeline of siRNA and combination…
Biokin Pharmaceutical
Building a Global Oncology Franchise Around Bispecific ADCs
Haisco Pharmaceutical Group
From Chinese Specialty Pharma to Global Innovative Drug Developer
Akeso, Inc.
Building a Global Bispecific Antibody and Next-Generation Oncology Franchise
CPHI & PMEC Shenzhen 2026
China is the world’s 2nd largest pharma market, which is valued at USD 282.07bn in 2024, and projected to reach USD 402bn by 2029. AI in pharma is surging at 41.52% CAGR, the fastest across all sectors. Why Shenzhen? Shenzhen’s 1,300+ biotech…